Sanofi: green light from CHMP for Zynquista
(CercleFinance.com) - Sanofi announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has delivered a favourable opinion for the application for marketing authorisation for Zynquista (sotagliflozin), jointly developed with Lexicon .
The CHMP has recommended that it be approved in the European Union, alongside insulin therapy to improve glycemic control of adults with type 1 diabetes whose body mass index is greater than or equal to 27 kg/m2.
The European Commission is expected to make its final decision on the application for marketing authorisation in the coming months. Sotagliflozin is also beint evaluated by the US FDA, which is expected to make its decision on 22 March 2019.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The CHMP has recommended that it be approved in the European Union, alongside insulin therapy to improve glycemic control of adults with type 1 diabetes whose body mass index is greater than or equal to 27 kg/m2.
The European Commission is expected to make its final decision on the application for marketing authorisation in the coming months. Sotagliflozin is also beint evaluated by the US FDA, which is expected to make its decision on 22 March 2019.
Copyright (c) 2019 CercleFinance.com. All rights reserved.